Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling
Nat Cancer
.
2022 Nov;3(11):1404.
doi: 10.1038/s43018-022-00487-7.
Authors
Ido Yofe
#
1
,
Tomer Landsberger
#
1
,
Adam Yalin
#
1
,
Isabelle Solomon
2
,
Cristobal Costoya
2
,
Dafne Franz Demane
2
,
Mansi Shah
2
,
Eyal David
1
,
Chamutal Borenstein
1
,
Oren Barboy
1
,
Ignacio Matos
2
,
Karl S Peggs
2
,
Sergio A Quezada
3
,
Ido Amit
4
Affiliations
1
Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel.
2
Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
3
Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK. s.quezada@ucl.ac.uk.
4
Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel. ido.amit@weizmann.ac.il.
#
Contributed equally.
PMID:
36376510
DOI:
10.1038/s43018-022-00487-7
No abstract available
Publication types
Published Erratum